T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1401
Park Hotels & Resorts
PK
$3.05B
| $4.66M | ﹤0.01% |
445,420
+29,497
| +7% | +$316K |
|
1402
Arrow Electronics
ARW
$10.7B
| $4.65M | ﹤0.01% |
42,179
+817
| +2% | +$92.8K |
|
1403
Macerich
MAC
$6.98B
| $4.62M | ﹤0.01% |
250,213
+9,919
| +4% | +$175K |
|
1404
Spire
SR
$4.89B
| $4.62M | ﹤0.01% |
55,826
+1,653
| +3% | +$141K |
|
1405
DigitalOcean
DOCN
$15.3B
| $4.61M | ﹤0.01% |
95,796
+36,658
| +62% | +$1.61M |
|
1406
AutoNation
AN
$6.91B
| $4.61M | ﹤0.01% |
22,325
+2,247
| +11% | +$467K |
|
1407
Mohawk Industries
MHK
$9.42B
| $4.59M | ﹤0.01% |
41,990
-33,702
| -45% | -$3.87M |
|
1408
Etsy
ETSY
$7.33B
| $4.55M | ﹤0.01% |
82,075
-313,644
| -79% | -$19.1M |
|
1409
QCR Holdings
QCRH
$1.74B
| $4.55M | ﹤0.01% |
54,562
+3,436
| +7% | +$270K |
|
1410
Celanese
CE
$4.96B
| $4.54M | ﹤0.01% |
107,277
+15,813
| +17% | +$645K |
|
1411
WisdomTree
WT
$3.45B
| $4.52M | ﹤0.01% |
370,422
-521,288
| -58% | -$6.3M |
|
|
GAP
1412
The Gap Inc
GAP
$7.41B
| $4.5M | ﹤0.01% |
175,832
+7,341
| +4% | +$178K |
|
1413
Magnolia Oil & Gas
MGY
$6.19B
| $4.5M | ﹤0.01% |
205,480
+4,541
| +2% | +$103K |
|
1414
Resideo Technologies
REZI
$3.13B
| $4.49M | ﹤0.01% |
127,665
+281
| +0.2% | +$10.4K |
|
1415
CRISPR Therapeutics
CRSP
$5.16B
| $4.46M | ﹤0.01% |
84,940
+8,405
| +11% | +$503K |
|
1416
FNB Corp
FNB
$6.92B
| $4.44M | ﹤0.01% |
259,498
+14,207
| +6% | +$232K |
|
1417
Atlantic Union Bankshares
AUB
$6.12B
| $4.44M | ﹤0.01% |
125,692
+4,858
| +4% | +$167K |
|
1418
Axos Financial
AX
$5.81B
| $4.44M | ﹤0.01% |
51,484
+2,138
| +4% | +$176K |
|
1419
Bentley Systems
BSY
$10.9B
| $4.42M | ﹤0.01% |
115,885
+5,848
| +5% | +$267K |
|
1420
Herc Holdings
HRI
$5.73B
| $4.4M | ﹤0.01% |
29,677
+889
| +3% | +$122K |
|
1421
Allogene Therapeutics
ALLO
$697M
| $4.4M | ﹤0.01% |
3,209,275
-468,199
| -13% | -$618K |
|
1422
iShares Russell Mid-Cap Growth ETF
IWP
$21.1B
| $4.39M | ﹤0.01% |
32,086
| – | – |
|
1423
Brunswick
BC
$5.29B
| $4.37M | ﹤0.01% |
58,809
+2,514
| +4% | +$170K |
|
|
CDTX
1424
DELISTED
Cidara Therapeutics
CDTX
| $4.36M | ﹤0.01% |
19,743
+11,219
| +132% | +$1.81M |
|
|
CNR
1425
Core Natural Resources Inc
CNR
$4.77B
| $4.35M | ﹤0.01% |
49,185
+2,379
| +5% | +$203K |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.